[go: up one dir, main page]

MA26674A1 - Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
MA26674A1
MA26674A1 MA25729A MA25729A MA26674A1 MA 26674 A1 MA26674 A1 MA 26674A1 MA 25729 A MA25729 A MA 25729A MA 25729 A MA25729 A MA 25729A MA 26674 A1 MA26674 A1 MA 26674A1
Authority
MA
Morocco
Prior art keywords
sup
preparation
pharmaceutical compositions
compositions containing
new heterocyclic
Prior art date
Application number
MA25729A
Other languages
English (en)
Inventor
Stanley Chupak Louis
Francis Mcclure Kim
Anthony Letavic Michael
Carl Noe Mark
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26674A1 publication Critical patent/MA26674A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
MA25729A 1998-08-12 1999-08-11 Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant MA26674A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9625698P 1998-08-12 1998-08-12

Publications (1)

Publication Number Publication Date
MA26674A1 true MA26674A1 (fr) 2004-12-20

Family

ID=22256553

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25729A MA26674A1 (fr) 1998-08-12 1999-08-11 Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (15)

Country Link
US (2) US20030181441A1 (fr)
EP (1) EP1104412B1 (fr)
JP (1) JP3623448B2 (fr)
AT (1) ATE297908T1 (fr)
AU (1) AU4925099A (fr)
BR (1) BR9912944A (fr)
CA (1) CA2340182A1 (fr)
DE (1) DE69925840T2 (fr)
ES (1) ES2242402T3 (fr)
GT (1) GT199900132A (fr)
MA (1) MA26674A1 (fr)
PA (1) PA8479901A1 (fr)
TN (1) TNSN99157A1 (fr)
UY (1) UY25992A1 (fr)
WO (1) WO2000009492A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (fr) 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1138680A1 (fr) * 2000-03-29 2001-10-04 Pfizer Products Inc. Acides gem-substitués alpha-sulfonylamino hydroxamiques comme inhibiteurs de métalloprotease
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
JP2005504043A (ja) 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
US7629341B2 (en) 2002-06-12 2009-12-08 Symphony Evolution, Inc. Human ADAM-10 inhibitors
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
CN1802375A (zh) * 2003-04-09 2006-07-12 千禧药品公司 用于治疗炎性疾病的β－咔啉
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
DE602005020263D1 (de) 2004-04-09 2010-05-12 Millennium Pharm Inc Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2007016597A2 (fr) * 2005-07-29 2007-02-08 The Regents Of The University Of California Ciblage de secretion de facteur de croissance dependant d'enzyme de conversion de tnf-alpha (tace) dans une therapie anticancereuse
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
IT1404729B1 (it) * 2011-01-27 2013-11-29 Univ Pisa Inibitori altamente selettivi dell'attivita' di adams
EP2763972A1 (fr) * 2011-10-04 2014-08-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Nouveaux composés induisant l'apoptose
CN111500721B (zh) * 2020-04-20 2022-11-29 青岛大学附属医院 Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK73898A3 (en) * 1995-12-08 1999-01-11 Agouron Pharma Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
JP2001506257A (ja) * 1996-12-17 2001-05-15 藤沢薬品工業株式会社 Ｍｍｐまたはｔｎｆ阻害剤としてのピペラジン化合物
JP3710489B2 (ja) * 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
EP1081137A1 (fr) * 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite

Also Published As

Publication number Publication date
TNSN99157A1 (fr) 2005-11-10
ATE297908T1 (de) 2005-07-15
JP2003526604A (ja) 2003-09-09
US20050215549A1 (en) 2005-09-29
UY25992A1 (es) 2000-03-31
US20030181441A1 (en) 2003-09-25
BR9912944A (pt) 2001-05-08
GT199900132A (es) 2001-02-02
CA2340182A1 (fr) 2000-02-24
ES2242402T3 (es) 2005-11-01
AU4925099A (en) 2000-03-06
DE69925840D1 (de) 2005-07-21
DE69925840T2 (de) 2006-05-04
EP1104412B1 (fr) 2005-06-15
PA8479901A1 (es) 2000-05-24
WO2000009492A1 (fr) 2000-02-24
JP3623448B2 (ja) 2005-02-23
EP1104412A1 (fr) 2001-06-06

Similar Documents

Publication Publication Date Title
MA26674A1 (fr) Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr) Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2279276A1 (fr) Derives d'acide arylsulfonylaminohydroxamique
NO990821L (no) Arylsulfonylamino-hydroksaminsyre-derivater
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
TNSN00111A1 (fr) Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ3023A1 (fr) Dérivés de résorcinol, compositions pharmaceutiques les contenant et procédé pour leur préparation.
TNSN00114A1 (fr) Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2830531B1 (fr) Acides naphtylsulfoniques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ3044A1 (fr) Dérivés de 1-trifluorométhyl-4-hydroxy-7-pipéridinyl-aminométhyl-chromane, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3047A1 (fr) Sel mutuel d'amlopidine et d'atorvastatine, procédé pour sa préparation et compositions pharmaceutiques les contenant.
Akdağ et al. Synthesis and biological evaluation of some new hydrazone derivatives bearing pyrimidine ring as analgesic and anti-inflammatory agents
DZ2748A1 (fr) Dérivés de quinoléine nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2802531B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant